Modra Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Modra Pharmaceuticals is a clinical-stage biotech company developing oral formulations of widely used intravenous taxane chemotherapies. Its proprietary technology platform combines optimized, water-soluble taxane tablets with a pharmacokinetic booster (ritonavir) to overcome poor oral bioavailability and enhance drug exposure. The company's lead program, ModraDoc006/r, is in Phase 2b development for metastatic castration-resistant prostate cancer (mCRPC), with the goal of offering equivalent efficacy with improved tolerability and a more convenient, patient-friendly administration. Founded as a spin-out from the Netherlands Cancer Institute, Modra is positioning itself to address a significant unmet need in the standard oncology care paradigm.

Oncology

Technology Platform

Proprietary platform for modulated oral drug absorption, combining optimized, water-soluble taxane tablets with a pharmacokinetic booster (ritonavir) to inhibit CYP3A4 and P-gp, thereby enhancing systemic and intratumoral drug bioavailability.

Opportunities

The global taxane market represents a multi-billion dollar opportunity.

An effective oral formulation could capture significant market share by offering improved patient quality of life, reduced healthcare system burden from infusions, and potentially better tolerability enabling longer treatment duration.

The platform technology is also applicable across multiple taxanes (docetaxel, paclitaxel, cabazitaxel) and solid tumor types, allowing for pipeline expansion.

Risk Factors

Key risks include clinical failure in pivotal trials to demonstrate non-inferior efficacy versus IV taxanes, regulatory challenges in approving an oral version of an established injectable, and intense competition from both improved IV formulations and novel therapeutic classes.

As a pre-revenue company, it also faces significant financing and dilution risk to fund late-stage development.

Competitive Landscape

Competition includes manufacturers of existing IV taxane generics and branded formulations like Abraxane (nab-paclitaxel). Other companies are exploring oral chemotherapy enhancers and novel taxane analogs. Modra's primary competitive edge is its focused approach on oral delivery of the exact same active ingredients, aiming for a seamless substitution in clinical practice based on improved tolerability and convenience.

More companies in Small Molecule Drugs →More companies in Netherlands →